| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39770248238389dd869fdaef87983879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14813ba46a31b6b6790569d56f5e388d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2570-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56977
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B30-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B30-00 |
| filingDate |
2022-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5e2bd77d21812d11c9331b9ab33f367
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e0e7b49ca30573d0791bb64a2c49cd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4489f18b69d35cd3853d4cac1bb2c9b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9db4286ec1ed72092019c46cf6aa25c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5cdb81f3765e2ecedab668bff7ba998
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f423e132c16eb4fd2794d9a4ff8fc27b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9da7d765d025ae1f308dd5edea3df9ab |
| publicationDate |
2022-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022165353-A1 |
| titleOfInvention |
Tumor antigenicity processing and presentation |
| abstract |
Methods for targeting a tumor antigen for immunotherapy based on HLA allele type and the mutations present in the tumor antigen are presented. A patient's HLA allele type and a tumor antigen derived from a mutation in cancer driver gene can be matched with a majority allele type having a minimum affinity to the same tumor antigen or with those of a plurality of patients with a history of cancer treatment. Upon matching, a cancer treatment against the tumor antigen can be selected and administered to the patient to achieve a desired effect. |
| priorityDate |
2016-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |